Browsing: Nordisk
Peter HansenNovo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people…
aprott/iStock via Getty ImagesRivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk (NVO)…
ismagilov Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with…
hapabapa/iStock Editorial via Getty Images IMMvention Therapeutix announced a strategic collaboration and license agreement with Novo Nordisk A/S (NVO) to…
aprott/iStock via Getty ImagesNovo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as…
hapabapa/iStock Editorial via Getty ImagesNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as…
CRNovo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading…
hapabapa/iStock Editorial via Getty ImagesNovo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared…